(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1744756

インスリン感受性促進薬の世界市場

Insulin Sensitizers

出版日
ページ情報
英文 340 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.50円
インスリン感受性促進薬の世界市場
出版日: 2025年06月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 340 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インスリン感受性促進薬の世界市場は2030年までに288億米ドルに達する見込み

2024年に217億米ドルと推定されるインスリン感受性促進薬の世界市場は、2024～2030年の分析期間にCAGR 4.8%で成長し、2030年には288億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるチアゾリジン系化合物は、CAGR 3.8%を記録し、分析期間終了時には131億米ドルに達すると予測されます。ビグアナイド系セグメントは、分析期間中にCAGR 6.5%の成長が見込まれます。

米国市場は59億米ドルと推定、中国はCAGR 7.5%で成長予測

米国のインスリン感受性促進薬市場は、2024年には59億米ドルになると推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 7.5%で推移し、2030年には予測市場規模が56億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と4.8%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界のインスリン感受性促進薬市場- 主要動向と促進要因のまとめ

なぜインスリン感受性促進薬が2型糖尿病と代謝性疾患の管理の中心なのか？

インスリン感受性促進薬は、2型糖尿病やメタボリックシンドロームの特徴であるインスリン抵抗性を持つ人のグルコースの取り込みと利用を改善することにより、インスリンに対する体の反応を高めるようにデザインされた重要な治療薬です。インスリン濃度に直接作用するインスリンやインスリン分泌促進薬とは異なり、インスリン感受性促進薬は筋肉、肝臓、脂肪組織などの末梢組織に作用し、内因性のインスリン分泌を刺激することなく、インスリン感受性を回復させ血糖コントロールを改善します。このメカニズムにより、代謝機能不全の根本原因の1つに対処しながら、低血糖のリスクを軽減します。

これらの治療薬は、特に肥満に関連したインスリン抵抗性を有する患者において、第一選択薬または第二選択薬の治療戦略の一部として広く使用されています。また、多嚢胞性卵巣症候群（PCOS）、非アルコール性脂肪性肝疾患（NAFLD）、糖尿病前症などの管理においても考慮されるようになってきています。インスリン感受性促進薬は、インスリン作用を改善し、肝グルコース産生を低下させることにより、空腹時血糖値、ヘモグロビンA1c値、および関連する心代謝リスクを低下させる。長期的な疾患調節におけるこれらの薬剤の役割は、慢性代謝疾患に対するより広範な治療において不可欠なものとなっています。

どのような薬理学的クラスと革新がインスリン増感薬治療を再構築しているのか？

インスリン抵抗性改善薬のカテゴリーは、チアゾリジン系薬剤（TZDs）とビグアナイド系薬剤という2つの主要な薬剤クラスによって代表されており、メトホルミンが世界で最も広く処方されている薬剤です。メトホルミンは、しばしば2型糖尿病管理の要と考えられており、主に肝グルコース産生を減少させ、末梢のインスリン感受性を改善することによって作用します。メトホルミンは、その有効性、安全性、体重の中立性、心血管系への有益性が確立されていることから支持されています。

ピオグリタゾンやロシグリタゾンなどのチアゾリジン系薬剤は、ペルオキシソーム増殖因子活性化受容体γ（PPAR-γ）を活性化することにより機能し、脂肪組織や骨格筋におけるインスリン応答性を亢進させる。効果的ではあるが、体液貯留、骨折、心血管系リスクの懸念から、その使用は控えめです。しかし、現在進行中の選択的PPARモジュレーターやデュアルPPAR-α/γアゴニストの研究は、TZDのグルコース低下効果を維持しつつ、副作用を最小限に抑えることを目的としています。

新たなインスリン感受性増強薬の候補としては、AMP活性化プロテインキナーゼ（AMPK）活性化薬、ミトコンドリア機能調節薬、炎症と脂質代謝を標的とした薬剤などがあります。また、新規の生物学的経路を通じてインスリン作用を改善する可能性のある、植物由来の生物活性物質や腸内細菌叢調節物質の研究も進められています。SGLT2阻害薬、GLP-1受容体作動薬、DPP-4阻害薬との合剤開発により、治療の多様性と患者のアドヒアランスがさらに向上しています。

インスリン感受性促進薬の需要を牽引している患者層と臨床動向は？

インスリン抵抗性改善薬使用の主な原動力は、2型糖尿病とインスリン抵抗性の世界の急増であり、特に高齢化社会、肥満患者、都市化と座りがちなライフスタイルを経験した人々の間で顕著です。特に、生活習慣に関連した代謝異常が急増している、疫学的に急速な転換期を迎えている地域での需要が大きいです。新たに糖尿病と診断された患者では、インスリン感受性促進薬、特にメトホルミンが、その費用対効果と良好なリスク・ベネフィット・プロファイルにより、第一選択薬として広く採用されています。

女性の健康においては、インスリン感受性促進薬は、インスリン抵抗性が月経不順、高アンドロゲン血症、不妊の一因となるPCOSに頻繁に処方されています。さらに、肝脂肪症を軽減し、肝酵素プロファイルを改善することから、NAFLDや代謝関連脂肪性肝疾患（MAFLD）の治療薬としても注目されています。糖尿病予備軍では、メトホルミンは、特にBMIが高く空腹時血糖が低下している患者において、予防療法として使用されることが多くなっています。これらの重複する適応により、インスリン感受性促進薬の役割はグルコースコントロールにとどまらず、より広範な代謝最適化へと拡大しつつあります。

インスリン感受性促進薬市場の成長はいくつかの要因によって牽引されている...

インスリン感受性促進薬市場の開拓は、2型糖尿病の世界の負担の増大、適応外治療用途の拡大、安全性プロファイルを改善した次世代薬剤の開発への継続的な取り組みなど、いくつかの要因によって推進されています。公衆衛生意識の高まり、早期診断への取り組み、インスリン抵抗性への早期介入を推奨する治療ガイドラインの更新により、患者数と処方率は増加しています。国際的な糖尿病管理プロトコールでメトホルミンが承認され続けていることも、メトホルミンの優位性と需要の持続を確実なものにしています。

新たな分子標的薬、併用療法、個別化投与戦略の開発により、医薬品の技術革新は加速しています。インスリン感受性促進薬の長期的な心保護効果や代謝改善効果を裏付ける現実のエビデンスは、包括的な糖尿病治療における臨床的妥当性を強化しています。さらに、肥満症やメタボリックシンドローム治療薬への投資が拡大していることから、新規増感剤の研究開発が活発化し、既存薬も適応拡大に向けて再配置されつつあります。ヘルスケアシステムが、疾患の進行を遅らせ、合併症を最小限に抑え、糖尿病の経済的負担を軽減することを目指している中、インスリン感受性促進薬は、今後も世界中で代謝性疾患管理の基礎となる要素であり続けるでしょう。

セグメント

インスリン感受性促進薬（チアゾリジン系薬剤、ビグアナイド系薬剤、インクレチン系薬剤、その他のインスリン感受性促進薬）;適応症（2型糖尿病、糖尿病予備軍、多嚢胞性卵巣症候群）;投与経路（経口剤、注射剤）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の44社）

  • Amgen Inc.
  • AstraZeneca
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chong Kun Dang Pharmaceutical Corp.
  • Eli Lilly and Company
  • Fractyl Health
  • Gan & Lee Pharmaceuticals
  • GSK（GlaxoSmithKline）
  • Imcyse
  • Ionis Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • MSDC-0602K（Cirius Therapeutics）
  • Novo Nordisk
  • Sanofi
  • Saroglitazar
  • Takeda Pharmaceutical Company
  • Zydus Lifesciences

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35240

Global Insulin Sensitizers Market to Reach US$28.8 Billion by 2030

The global market for Insulin Sensitizers estimated at US$21.7 Billion in the year 2024, is expected to reach US$28.8 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Thiazolidinediones, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$13.1 Billion by the end of the analysis period. Growth in the Biguanides segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 7.5% CAGR

The Insulin Sensitizers market in the U.S. is estimated at US$5.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Insulin Sensitizers Market - Key Trends & Drivers Summarized

Why Are Insulin Sensitizers Central to the Management of Type 2 Diabetes and Metabolic Disorders?

Insulin sensitizers are a critical class of therapeutic agents designed to enhance the body's response to insulin, thereby improving glucose uptake and utilization in individuals with insulin resistance-a hallmark of type 2 diabetes and metabolic syndrome. Unlike insulin or insulin secretagogues, which directly affect insulin levels, insulin sensitizers act on peripheral tissues such as muscle, liver, and adipose tissue to restore insulin sensitivity and improve glycemic control without stimulating endogenous insulin secretion. This mechanism reduces the risk of hypoglycemia while addressing one of the root causes of metabolic dysfunction.

These drugs are widely used as part of first- or second-line treatment strategies, particularly in patients with obesity-related insulin resistance. They are also increasingly considered in the management of polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and prediabetes. By improving insulin action and reducing hepatic glucose output, insulin sensitizers help lower fasting plasma glucose, hemoglobin A1c levels, and associated cardiometabolic risks. Their role in long-term disease modulation makes them indispensable in the broader landscape of chronic metabolic care.

What Pharmacological Classes and Innovations Are Reshaping Insulin Sensitizer Therapies?

The insulin sensitizer category is largely represented by two major drug classes: thiazolidinediones (TZDs) and biguanides, with metformin being the most widely prescribed agent worldwide. Metformin, often considered the cornerstone of type 2 diabetes management, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. It is favored for its well-established efficacy, safety, weight neutrality, and cardiovascular benefits.

Thiazolidinediones, such as pioglitazone and rosiglitazone, function by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to enhanced insulin responsiveness in adipose tissue and skeletal muscle. While effective, their use is moderated due to concerns around fluid retention, bone fractures, and cardiovascular risk. However, ongoing research into selective PPAR modulators and dual PPAR-α/γ agonists aims to retain the glucose-lowering benefits of TZDs while minimizing adverse effects.

Emerging insulin sensitizer candidates include AMP-activated protein kinase (AMPK) activators, mitochondrial function modulators, and agents targeting inflammation and lipid metabolism. Research is also exploring plant-derived bioactives and gut microbiome modulators for their potential to improve insulin action through novel biological pathways. The development of fixed-dose combinations with SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors is further enhancing therapeutic versatility and patient adherence.

Which Patient Populations and Clinical Trends Are Driving Demand for Insulin Sensitizers?

The primary driver of insulin sensitizer use is the global surge in type 2 diabetes and insulin resistance, particularly among aging populations, individuals with obesity, and populations experiencing urbanization and sedentary lifestyles. The demand is especially strong in regions experiencing rapid epidemiological transitions, where lifestyle-related metabolic disorders are rising sharply. In newly diagnosed diabetic patients, insulin sensitizers-especially metformin-are widely adopted as first-line therapy due to their cost-effectiveness and favorable risk-benefit profile.

In women’s health, insulin sensitizers are frequently prescribed for PCOS, where insulin resistance contributes to menstrual irregularities, hyperandrogenism, and subfertility. Additionally, they are gaining traction in managing NAFLD and metabolic-associated fatty liver disease (MAFLD), given their ability to reduce hepatic steatosis and improve liver enzyme profiles. In prediabetic individuals, metformin is increasingly used as a preventive therapy, especially in patients with high BMI and impaired fasting glucose. These overlapping indications are expanding the role of insulin sensitizers beyond glucose control to broader metabolic optimization.

The Growth in the Insulin Sensitizers Market Is Driven by Several Factors…

The growth in the insulin sensitizers market is driven by several factors including the escalating global burden of type 2 diabetes, expanding off-label therapeutic applications, and ongoing efforts to develop next-generation agents with improved safety profiles. Rising public health awareness, early diagnosis initiatives, and updated treatment guidelines that recommend early intervention in insulin resistance are increasing patient volumes and prescription rates. The continued endorsement of metformin in international diabetes management protocols also ensures its dominance and sustained demand.

Pharmaceutical innovation is accelerating with the development of new molecular targets, combination therapies, and personalized dosing strategies. Real-world evidence supporting the long-term cardioprotective and metabolic benefits of insulin sensitizers is reinforcing their clinical relevance in comprehensive diabetes care. Additionally, growing investment in obesity and metabolic syndrome therapeutics is boosting R&D around novel sensitizers and repositioning existing agents for expanded indications. As healthcare systems aim to delay disease progression, minimize complications, and reduce the economic burden of diabetes, insulin sensitizers are poised to remain a foundational component of metabolic disorder management worldwide.

SCOPE OF STUDY:

The report analyzes the Insulin Sensitizers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Insulin Sensitizers (Thiazolidinediones, Biguanides, Incretin-based Therapies, Other Insulin Sensitizers); Indication (Type 2 Diabetes, Prediabetes, Polycystic Ovary Syndrome); Administration Route (Oral, Injectable); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amgen Inc.
  • AstraZeneca
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chong Kun Dang Pharmaceutical Corp.
  • Eli Lilly and Company
  • Fractyl Health
  • Gan & Lee Pharmaceuticals
  • GSK (GlaxoSmithKline)
  • Imcyse
  • Ionis Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • MSDC-0602K (Cirius Therapeutics)
  • Novo Nordisk
  • Sanofi
  • Saroglitazar
  • Takeda Pharmaceutical Company
  • Zydus Lifesciences

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Insulin Sensitizers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Type 2 Diabetes Propels Demand for Insulin Sensitizers as a Core Therapeutic Class
    • Shift Toward Early Intervention and Combination Therapy Strengthens Use of Insulin Sensitizers Alongside GLP-1 and SGLT2 Inhibitors
    • Increasing Clinical Focus on Metabolic Syndrome and Insulin Resistance Expands Off-Label and Adjunctive Use of Sensitizing Agents
    • Ongoing Development of Next-Generation Thiazolidinediones (TZDs) With Reduced Side Effects Drives Pipeline Innovation
    • Growing Emphasis on Personalized Medicine in Diabetes Care Spurs Interest in Pharmacogenomics-Guided Insulin Sensitizer Therapies
    • Rising Incidence of Obesity-Linked Diabetes Highlights the Role of Insulin Sensitizers in Improving Adipose Tissue Sensitivity
    • Emergence of Dual and Triple Mechanism Therapies Encourages Integration of Insulin Sensitizers With Incretin-Based Agents
    • Increasing Research Into PCOS and NAFLD Expands Therapeutic Use Cases for Metformin and TZD-Class Sensitizers
    • Declining Cost of Generic Metformin Sustains Widespread First-Line Adoption in Low- and Middle-Income Countries
    • Regulatory Push for Safer Diabetic Medications Promotes Reformulation of Older TZDs With Improved Safety Profiles
    • Pharmaceutical Investment in Oral Antidiabetic Combinations Enhances Commercial Viability of Insulin Sensitizer Co-Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Insulin Sensitizers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Insulin Sensitizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Insulin Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Thiazolidinediones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Thiazolidinediones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Incretin-based Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Incretin-based Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Insulin Sensitizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Insulin Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Polycystic Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Polycystic Ovary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • JAPAN
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • CHINA
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 52: China Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • EUROPE
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Insulin Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • FRANCE
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • GERMANY
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • UNITED KINGDOM
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 94: UK Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • SPAIN
    • TABLE 102: Spain Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Spain 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 104: Spain Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Spain 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 106: Spain Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Spain 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 108: Spain Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Spain 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • RUSSIA
    • TABLE 110: Russia Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Russia 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 112: Russia Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Russia 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 114: Russia Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Russia 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 116: Russia Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Russia 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Europe 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • AUSTRALIA
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 136: Australia Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Australia 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 138: Australia Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Australia 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 140: Australia Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Australia 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 142: Australia Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Australia 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • INDIA
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 144: India Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: India 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 146: India Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: India 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 148: India Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: India 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 150: India Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: India 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 152: South Korea Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: South Korea 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 154: South Korea Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: South Korea 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 156: South Korea Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: South Korea 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 158: South Korea Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: South Korea 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 160: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 162: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 163: Rest of Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 164: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Rest of Asia-Pacific 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • LATIN AMERICA
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 168: Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 169: Latin America 6-Year Perspective for Insulin Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 170: Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Latin America 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 172: Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Latin America 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 174: Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Latin America 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 176: Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Latin America 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 178: Argentina Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Argentina 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 180: Argentina Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Argentina 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 182: Argentina Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Argentina 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 184: Argentina Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Argentina 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • BRAZIL
    • TABLE 186: Brazil Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Brazil 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 188: Brazil Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Brazil 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 190: Brazil Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: Brazil 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 192: Brazil Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: Brazil 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • MEXICO
    • TABLE 194: Mexico Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Mexico 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 196: Mexico Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Mexico 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 198: Mexico Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Mexico 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 200: Mexico Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Mexico 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 202: Rest of Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Rest of Latin America 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 204: Rest of Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Rest of Latin America 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 206: Rest of Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Latin America 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 209: Rest of Latin America 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • MIDDLE EAST
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 210: Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 211: Middle East 6-Year Perspective for Insulin Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 212: Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Middle East 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 214: Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 215: Middle East 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 216: Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 217: Middle East 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 218: Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Middle East 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • IRAN
    • TABLE 220: Iran Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 221: Iran 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 222: Iran Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 223: Iran 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 224: Iran Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Iran 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 226: Iran Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 227: Iran 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • ISRAEL
    • TABLE 228: Israel Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 229: Israel 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 230: Israel Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Israel 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 232: Israel Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 233: Israel 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 234: Israel Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 235: Israel 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 236: Saudi Arabia Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Saudi Arabia 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 238: Saudi Arabia Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 239: Saudi Arabia 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 240: Saudi Arabia Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 241: Saudi Arabia 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Saudi Arabia 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 244: UAE Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 245: UAE 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 246: UAE Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 247: UAE 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 248: UAE Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: UAE 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 250: UAE Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 251: UAE 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 252: Rest of Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 253: Rest of Middle East 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 254: Rest of Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Middle East 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 256: Rest of Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 257: Rest of Middle East 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 259: Rest of Middle East 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030
  • AFRICA
    • Insulin Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 260: Africa Recent Past, Current & Future Analysis for Insulin Sensitizers by Insulin Sensitizers - Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Africa 6-Year Perspective for Insulin Sensitizers by Insulin Sensitizers - Percentage Breakdown of Value Sales for Thiazolidinediones, Biguanides, Incretin-based Therapies and Other Insulin Sensitizers for the Years 2025 & 2030
    • TABLE 262: Africa Recent Past, Current & Future Analysis for Insulin Sensitizers by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 263: Africa 6-Year Perspective for Insulin Sensitizers by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
    • TABLE 264: Africa Recent Past, Current & Future Analysis for Insulin Sensitizers by Indication - Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 265: Africa 6-Year Perspective for Insulin Sensitizers by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Prediabetes and Polycystic Ovary Syndrome for the Years 2025 & 2030
    • TABLE 266: Africa Recent Past, Current & Future Analysis for Insulin Sensitizers by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Africa 6-Year Perspective for Insulin Sensitizers by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2025 & 2030

IV. COMPETITION